Original language | English (US) |
---|---|
Pages (from-to) | 5057-5059 |
Number of pages | 3 |
Journal | Blood Advances |
Volume | 5 |
DOIs | |
State | Published - Dec 14 2021 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood Advances, Vol. 5, 14.12.2021, p. 5057-5059.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported
AU - Anekpuritanang, Tauangtham
AU - Klairmont, Matthew M.
AU - Gradowski, Joel
AU - Hagiwara, Kohei
AU - Bailey, Nathanael G.
AU - Chandra, Pranil
AU - Liu, Yiwei
AU - Mulder, Heather L.
AU - Easton, John
AU - Zhang, Jinghui
AU - Martin, Michael G.
AU - Owczarczyk, Anna B.
AU - Dunlap, Jennifer B.
AU - Fan, Guang
AU - Press, Richard D.
AU - Raess, Philipp W.
N1 - Funding Information: Acknowledgments: Biostatistics support was provided by the Biostatistics Shared Resource, Knight Cancer Institute (National Institutes of Health National Cancer Institute P30CA069533) (E.L. and B.P.) Contribution: T.A. designed experiments, analyzed data, and wrote the manuscript; M.M.K. designed experiments, analyzed data, and edited the manuscript; J.G., P.C., and A.B.O. contributed cases; K.H. analyzed data and edited the manuscript; N.G.B. contributed cases and edited the manuscript; Y.L., H.L.M., J.E., and J.Z. analyzed data; M.G.M. designed experiments, reviewed the manuscript, and provided funding; J.B.D., G.F., and R.D.P. analyzed data and edited the manuscript; and P.W.R. designed experiments, analyzed data, and wrote the manuscript.
PY - 2021/12/14
Y1 - 2021/12/14
UR - http://www.scopus.com/inward/record.url?scp=85121731933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121731933&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021004983
DO - 10.1182/bloodadvances.2021004983
M3 - Letter
C2 - 34559205
AN - SCOPUS:85121731933
SN - 2473-9529
VL - 5
SP - 5057
EP - 5059
JO - Blood Advances
JF - Blood Advances
ER -